Loading
IMP1734 is a small-molecule inhibitor from Eikon Therapeutics, in registered phase 2 trials for metastatic cancer.
IMP1734 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Eikon Therapeutics, in metastatic cancer. Described in the registry record as a parp1 selective inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
Described in the registry record as a parp1 selective inhibitor; the trial entries below carry the sponsor's wording.
1.IMP1734 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"IMP1734" OR ABSTRACT:"IMP1734") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IMP1734, not a curated reading list.
Shares Eikon Therapeutics and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Eikon Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.